Many biotech companies treat healthcare compliance as something to “scale later.” In reality, Phase III is the moment when compliance shifts from optional structure to operational necessity. Ignore that transition and risk begins accumulating faster than most leadership teams expect.
As organisations approach registration and launch readiness, their stakeholder footprint expands rapidly across investigators, healthcare professionals (HCPs), patient organisations, distributors, regulators, and payers. At the same time, expectations from frameworks such as the EFPIA Code and national transparency regimes become unavoidable.
Where Phase III Companies Commonly Get Caught Out
- advisory boards organised without documented Fair Market Value (FMV) justification
- investigator meetings drifting into promotional positioning before approval
- distributor onboarding without structured due diligence in higher-risk jurisdictions
- early market-shaping conversations with payers lacking internal governance oversight
- transfers of value tracked inconsistently across affiliates or vendors
- local country requirements such as France transparency pre-notification missed because responsibility is unclear
Compliance Enables Launch Readiness. It Does Not Slow It
Strong compliance frameworks at Phase III do not mean building “big pharma infrastructure.” They mean building the right foundations early:
- proportionate policies aligned to real activities
- a defensible FMV methodology
- structured third-party risk assessment
- transparency tracking across markets
- engagement governance for HCPs and patient organisations
- practical escalation pathways for medical versus promotional boundaries
Done properly, these systems accelerate decision-making rather than restrict it.
They also reduce friction when entering Europe, where country-level expectations differ significantly even within harmonised regulatory environments.
The Hidden Risk: Commercial Activity Starts Earlier Than You Think
Strong compliance frameworks at Phase III do not mean building “big pharma infrastructure.” They mean building the right foundations early:
Examples include:
- payer evidence discussions during market access preparation
- disease awareness initiatives
- advisory boards informing positioning strategy
- early distributor negotiations outside core territories
These are legitimate activities, but they require structure.
Without documentation, oversight, and alignment with local requirements, they can quickly fall outside defensible compliance boundaries.
Scalable Compliance Is Achievable Without Heavy Systems
Lean frameworks built on structured workflows, often within existing environments like Microsoft 365, can support:
- engagement approvals
- materials lifecycle tracking
- transparency data capture
- policy accessibility
- role-based training delivery
This creates audit-ready discipline without unnecessary complexity.
A Strategic Opportunity, Not Just a Risk Mitigation Exercise
Compliance maturity signals credibility to regulators, partners, investors, and future affiliates. It strengthens licensing discussions, supports European expansion, and reduces delays during launch preparation.
Most importantly, it allows leadership teams to scale engagement confidently rather than cautiously.
